Clinical trialNCT06885034RecruitingPhase 1/PHASE2Interventional

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

SponsorGlaxoSmithKlineEnrollment451Gastrointestinal Neoplasms

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

85 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Gsk Investigational Site
Heidelberg, Victoria, Australia
Niall Tebbutt
Recruiting
Gsk Investigational Site
Melbourne, Victoria, Australia
Jeanne Tie
Recruiting

Belgium

Gsk Investigational Site
Bonheiden, Belgium
Pieter-Jan Cuyle
Recruiting
Gsk Investigational Site
Brussels, Belgium
Marc Van den Eynde
Recruiting
Gsk Investigational Site
Leuven, Belgium
Gertjan Rasschaert
Recruiting
Gsk Investigational Site
Roeselare, Belgium
Sofie De Meulder
Recruiting

Brazil

Gsk Investigational Site
Porto Alegre, Brazil
Alan Azambuja
Recruiting
Gsk Investigational Site
São Paulo, Brazil
Camila Motta Venchiarutti Moniz
Recruiting
Gsk Investigational Site
Teresina, Brazil
Claudio Lima Rocha
Recruiting

Canada

Gsk Investigational Site
Calgary, Alberta, Canada
Richard Lee-Ying
Recruiting
Gsk Investigational Site
Toronto, Ontario, Canada
Eric Chen
Recruiting
Gsk Investigational Site
Montreal, Quebec, Canada
Francine Aubin
Recruiting
Gsk Investigational Site
Sherbrooke, Quebec, Canada
Frederic Lemay
Recruiting

Finland

Gsk Investigational Site
Helsinki, Finland
Sari Jaamaa
Recruiting
Gsk Investigational Site
Helsinki, Finland
Tuomo Alanko
Recruiting
Gsk Investigational Site
Kuopio, Finland
Okko Kääriäinen
Recruiting
Gsk Investigational Site
Tampere, Finland
Pia Osterlund
Recruiting

France

Gsk Investigational Site
Dijon, France
Côme Lepage
Recruiting
Gsk Investigational Site
Marseille, France
Emmanuel MITRY
Recruiting
Gsk Investigational Site
Paris, France
Thomas Aparicio
Recruiting
Gsk Investigational Site
Paris, France
Thierry Andre
Recruiting
Gsk Investigational Site
Paris, France
Julien Taieb
Recruiting
Gsk Investigational Site
Poitiers, France
David Tougeron
Recruiting
Gsk Investigational Site
Rennes, France
Julien EDELINE
Recruiting
Gsk Investigational Site
Villejuif, France
Michel Ducreux
Recruiting

Germany

Gsk Investigational Site
Bochum, Germany
Anke Reinacher Schick
Recruiting
Gsk Investigational Site
Düsseldorf, Germany
Christoph Roderburg
Recruiting
Gsk Investigational Site
Frankfurt, Germany
Thorsten Oliver Goetze
Recruiting
Gsk Investigational Site
Lübeck, Germany
Jens Kisro
Recruiting
Gsk Investigational Site
München, Germany
Stefan Boeck
Recruiting

Italy

Gsk Investigational Site
Milan, Italy
Filippo Pietrantonio
Recruiting
Gsk Investigational Site
Milan, Italy
Salvatore Siena
Recruiting
Gsk Investigational Site
Pisa, Italy
Chiara Cremolini
Recruiting
Gsk Investigational Site
Roma, Italy
Gennaro Daniele
Recruiting

Japan

Gsk Investigational Site
Aichi, Japan
Kei Muro
Recruiting
Gsk Investigational Site
Chiba, Japan
Akihito Kawazoe
Recruiting
Gsk Investigational Site
Hokkaido, Japan
Yoshito Komatsu
Recruiting
Gsk Investigational Site
Osaka, Japan
Taroh Satoh
Recruiting
Gsk Investigational Site
Tokyo, Japan
Toshiharu Hirose
Recruiting
Gsk Investigational Site
Tokyo, Japan
Kensei Yamaguchi
Recruiting

45 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Drug 1Drug 2Drug 3Drug 4Risvutatug rezetecan

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 Jun 2025
Primary completion: 10 Jan 2028
Completion: 9 Jan 2029
Last update posted: 3 Aug 2026
Registered enrollment: 451
Registry id: NCT06885034

Cross-registrations

EU-CTR / CTIS (EudraCT)2025-520672-26-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.